Tirzepatide vs Semaglutide: What's the Difference?

GLP-1 medications have transformed obesity treatment, and two names dominate the conversation: tirzepatide (sold as Mounjaro for type 2 diabetes and Zepbound for weight loss) and semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss). Both work, both have changed lives — but they work differently, produce different results, and have meaningfully different side effect profiles.

The core difference: one receptor vs two

Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a hormone that reduces appetite, slows stomach emptying, and helps regulate blood sugar. This is a single mechanism, and it's genuinely powerful.

Tirzepatide is a dual agonist — it targets both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptors are found in fat tissue, and activating them appears to enhance the GLP-1 effects significantly. This dual mechanism is widely believed to be why tirzepatide tends to produce greater weight loss than semaglutide at comparable doses.

Weight loss results: what the data shows

Clinical trial data tells a clear story:

• Semaglutide (Wegovy): Average weight loss of approximately 15% of body weight over 68 weeks in the STEP trials
• Tirzepatide (Zepbound): Average weight loss of approximately 20–22% of body weight over 72 weeks in the SURMOUNT trials

That 5–7 percentage point difference is significant. For someone starting at 250 lbs, it's the difference between losing 37 lbs and losing 52 lbs on average. Tirzepatide also had a higher proportion of patients achieving 20%+ weight loss.

That said, individual results vary enormously. Some people respond better to semaglutide. Clinical averages don't predict individual outcomes.

Side effects: more similar than different

Both medications share a similar side effect profile because they both activate GLP-1 receptors. Nausea, vomiting, diarrhea, and constipation are the most common with both. The same management strategies apply: slow titration, small meals, adequate hydration.

Where they differ: tirzepatide users report slightly higher rates of nausea in early weeks, possibly because the dual mechanism is more potent. Semaglutide users sometimes report more pronounced anxiety or mood changes, though evidence here is less clear.

Cost and access

Both medications are expensive without insurance — typically $900–$1,300/month at retail. Coverage varies significantly by insurer and indication (diabetes vs weight loss). Tirzepatide has been approved for weight loss (as Zepbound) more recently than semaglutide (Wegovy), so insurance coverage for the weight loss indication is still expanding.

Compounded versions of both have been available during shortage periods, though FDA policy on compounded GLP-1s is evolving rapidly.

Switching between medications

Some people switch from semaglutide to tirzepatide due to plateaus or tolerability issues, or vice versa. This is done under medical supervision — the dosing schedules and titration approaches differ. If you switch, tracking your response to the new medication from day one is especially valuable, since you're essentially starting a new titration curve.

Which is better?

Based on the data, tirzepatide produces greater average weight loss. But "better" depends on your individual response, insurance coverage, access, and tolerability. The best medication is the one you can access, afford, and tolerate well enough to stay on consistently.

Regardless of which you're on, consistent tracking of weight, food, injections, and wellness gives you the data to understand your own response — which is ultimately more useful than population averages.